- Home
- TVRD vs MNPR Comparison
TVRD vs MNPR Comparison
Compare TVRD & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- MNPR
- Stock Information
- Founded
- TVRD 2017
- MNPR 2014
- Country
- TVRD United States
- MNPR United States
- Employees
- TVRD N/A
- MNPR N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- TVRD Health Care
- MNPR Health Care
- Exchange
- TVRD Nasdaq
- MNPR Nasdaq
- Market Cap
- TVRD 246.5M
- MNPR 248.8M
- IPO Year
- TVRD N/A
- MNPR 2019
- Fundamental
- Price
- TVRD $29.92
- MNPR $34.15
- Analyst Decision
- TVRD Strong Buy
- MNPR Strong Buy
- Analyst Count
- TVRD 5
- MNPR 8
- Target Price
- TVRD $59.20
- MNPR $63.14
- AVG Volume (30 Days)
- TVRD 23.2K
- MNPR 33.8K
- Earning Date
- TVRD 08-14-2025
- MNPR 08-12-2025
- Dividend Yield
- TVRD N/A
- MNPR N/A
- EPS Growth
- TVRD N/A
- MNPR N/A
- EPS
- TVRD N/A
- MNPR N/A
- Revenue
- TVRD N/A
- MNPR N/A
- Revenue This Year
- TVRD N/A
- MNPR N/A
- Revenue Next Year
- TVRD N/A
- MNPR N/A
- P/E Ratio
- TVRD N/A
- MNPR N/A
- Revenue Growth
- TVRD N/A
- MNPR N/A
- 52 Week Low
- TVRD $8.13
- MNPR $2.25
- 52 Week High
- TVRD $34.31
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- TVRD 65.43
- MNPR 45.88
- Support Level
- TVRD $22.91
- MNPR $29.18
- Resistance Level
- TVRD $31.54
- MNPR $37.56
- Average True Range (ATR)
- TVRD 1.65
- MNPR 3.01
- MACD
- TVRD 0.61
- MNPR 0.15
- Stochastic Oscillator
- TVRD 81.28
- MNPR 59.30
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.